STOCK TITAN
  1. Home
  2. News
  3. NTRB

Nutriband Inc. - NTRB STOCK NEWS

Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.

Nutriband Inc. (NASDAQ:NTRB) is a pioneering health and pharmaceutical company headquartered in Oviedo, Florida, with a core focus on transdermal and topical technologies for product development. The company is well-known for its innovative approach to drug delivery, particularly through its proprietary AVERSA™ technology, which aims to prevent the abuse, misuse, diversion, and accidental exposure of transdermal patches containing drugs with abuse potential such as opioids.

Nutriband's flagship product is the AVERSA™ Fentanyl patch, which integrates its abuse-deterrent technology with an FDA-approved transdermal fentanyl patch. This breakthrough product is designed to address the serious issue of transdermal patch abuse and accidental pediatric exposure, which according to recent data, continues to result in major medical outcomes and even death. The AVERSA™ Fentanyl patch has the potential to be the first opioid patch with abuse-deterrent properties and is estimated to reach peak annual US sales of $80M - $200M.

The company's innovative approach includes a portfolio of abuse-deterrent transdermal products targeting drugs such as buprenorphine and methylphenidate, which are prone to the risk of abuse and misuse. Nutriband utilizes its proprietary taste aversion technology, which makes the patches unappealing and difficult to tamper with, thereby reducing the likelihood of recreational abuse or accidental ingestion by children.

In addition to its pharmaceutical advancements, Nutriband Inc. has expanded its portfolio through its wholly-owned subsidiary, Active Intelligence, which focuses on the manufacturing of Kinesiology Tapes and has partnered with major fitness brands like Reebok and Adidas.

Recent developments include the completion of an $8.4 million private placement to fund the commercial development of AVERSA™ Fentanyl and its anticipated NDA filing with the FDA in Q1 2025. This funding will support the pivotal laboratory and clinical studies required for regulatory approval. Nutriband intends to leverage the 505(b)(2) NDA regulatory pathway, which streamlines approval for drugs that have been previously approved, thereby reducing the need for extensive clinical trials.

For more detailed information, visit the company's website at www.nutriband.com.

News

Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group

Rhea-AI Summary
Nutriband Inc. has signed an exclusive supplier agreement with Fit For Life Group, a major brand license holder, for the launch of a new product under one of their top brands. The agreement was fully executed on April 19, 2024. Nutriband's subsidiary, Active Intelligence, will serve as the manufacturer. Fit For Life Group, founded in 2016, is a prominent player in the fitness equipment and yoga accessories market, with a strong brand portfolio including Gaiam, Reebok, Adidas, New Balance, SPRI, and FILA. They target a wide range of consumers from beginners to professionals, with distribution through major retailers like Target, Walmart, Dick's Sporting Goods, and Amazon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
News

Nutriband Inc. Announces $8.4M Private Placement

Rhea-AI Summary
Nutriband Inc. has announced an $8.4M private placement to fund the development of AVERSA™ Fentanyl and target FDA approval in Q1 2025. The company has entered into securities purchase agreements for the sale of 2,100,000 shares of common stock at $4 per share, with investors receiving warrants to purchase additional shares at $6.43 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
-
News

Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance

Rhea-AI Summary
Nutriband Inc. announces engagement with Fit For Life Group, a major brand license holder, for manufacturing innovative products. Fit For Life Group, a market leader in fitness equipment and yoga accessories, has partnered with Nutriband to create innovative products for a wide range of consumers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.96%
Tags
none
News

Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch

Rhea-AI Summary
Nutriband Inc. announces the development of AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal patch, through a 505(b)(2) New Drug Application (NDA) pathway. Partnering with Kindeva Drug Delivery, Nutriband aims to revolutionize the opioid market by incorporating their AVERSA™ technology into FDA-approved transdermal fentanyl patches. The NDA submission will be based on a single Phase 1 human abuse potential clinical study, eliminating the need for Phase 2 or 3 trials. This streamlined regulatory process could lead to expedited FDA review, potentially making AVERSA™ Fentanyl the first abuse-deterrent patch approved globally. Market analysis projects peak annual US sales of $80 million to $200 million for AVERSA™ Fentanyl, tapping into the $22.8 billion global opioid market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.22%
Tags
none
-
News

Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting

Rhea-AI Summary
Nutriband Inc. presents data on transdermal patch abuse and accidental pediatric exposure at the 2024 AAPM Annual Meeting. The company's AVERSA™ technology aims to provide safer abuse-deterrent transdermal patches for opioid and stimulant drugs, addressing a critical unmet need in the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
-
News

Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting

Rhea-AI Summary
Nutriband Inc. announces data on transdermal patch abuse and accidental exposure to be presented at the 2024 AAPM Annual Meeting. The company collaborated with RMPDS to determine abuse rates in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
none
News

Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st

Rhea-AI Summary
Nutriband Inc. (NTRB) is set to present at The Microcap Conference in Atlantic City from January 30th to February 1st. CEO Gareth Sheridan will deliver two presentations and address questions. The company aims to showcase its potential to investors and traders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
conferences
-
News

Nutriband CEO Publishes Letter to Shareholders

Rhea-AI Summary
Nutriband Inc. CEO Gareth Sheridan published a letter to shareholders outlining the company's achievements in 2023 and targets for 2024. The company made significant strides in developing transdermal pharmaceutical products, securing new IP, and signing a commercial development and clinical supply agreement with Kindeva Drug Delivery for AVERSA Fentanyl, estimated to potentially reach peak annual sales of $80M - $200M. The company also reported strong revenue growth in 2023 and aims to expand its revenue opportunities through marketing initiatives and new product launches in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
none
-
News

Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch

Rhea-AI Summary
Nutriband Inc. (NTRB) announced a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with Kindeva Drug Delivery. The agreement aims to support a New Drug Application (NDA) with the FDA, replacing a previous feasibility agreement. Aversa™ Fentanyl is estimated to have the potential to reach peak annual US sales of $80M - $200M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.14%
Tags
none
News

Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling

Rhea-AI Summary
Nutriband Inc. (NTRB) launches Heating and Cooling Kinesiology Tape under AI Tape brand, offering pain-relieving ingredients for temporary relief of minor aches and pains. The product is the second launch this year, manufactured in the USA at Nutriband's facility in North Carolina, and available for purchase on Amazon and Activeintell.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.72%
Tags
AI

FAQ

What is the current stock price of Nutriband (NTRB)?

The current stock price of Nutriband (NTRB) is $4.45 as of January 7, 2025.

What is the market cap of Nutriband (NTRB)?

The market cap of Nutriband (NTRB) is approximately 52.5M.

What is Nutriband Inc.'s primary focus?

Nutriband Inc. focuses on developing transdermal and topical pharmaceutical products, with a key emphasis on abuse-deterrent technologies.

What is AVERSA™ technology?

AVERSA™ technology is Nutriband's proprietary abuse-deterrent transdermal technology designed to prevent the misuse, abuse, and accidental exposure of transdermal patches containing drugs with abuse potential.

What is the AVERSA™ Fentanyl patch?

The AVERSA™ Fentanyl patch integrates Nutriband’s abuse-deterrent technology with an FDA-approved transdermal fentanyl patch, aiming to reduce the risk of abuse and accidental exposure.

What recent achievements has Nutriband Inc. made?

Nutriband Inc. recently completed an $8.4 million private placement to fund the commercial development of AVERSA™ Fentanyl and plans to file an NDA with the FDA in Q1 2025.

What partnerships does Nutriband Inc. have?

Nutriband Inc. collaborates with Kindeva Drug Delivery for developing AVERSA™ Fentanyl and has partnered with fitness brands like Reebok and Adidas through its subsidiary, Active Intelligence.

What are the potential market sales for AVERSA™ Fentanyl?

The AVERSA™ Fentanyl patch is estimated to reach peak annual US sales of $80 million to $200 million.

What is the significance of the 505(b)(2) NDA regulatory pathway for Nutriband?

The 505(b)(2) NDA pathway allows Nutriband to reference existing data for previously approved drugs, reducing the need for extensive clinical trials and expediting the approval process.

How does Nutriband address accidental pediatric exposure to fentanyl patches?

Nutriband's AVERSA™ technology employs taste aversion agents to make patches unappealing, thereby preventing accidental pediatric exposure and ingestion.

What other products are in Nutriband’s development pipeline?

Nutriband is developing abuse-deterrent versions of other transdermal patches containing drugs like buprenorphine and methylphenidate.

Where can I get more information about Nutriband Inc.?

For more detailed information, visit Nutriband Inc.’s website at www.nutriband.com.
Stock NTRB logo
Nutriband Inc.

Nasdaq:NTRB

NTRB Rankings

#4904 Ranked by Market Cap
N/A Ranked by Dividends

NTRB Stock Data

52.53M
3.30M
54.05%
2.38%
0.5%
Biotechnology
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
ORLANDO